Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin

Blood. 2003 Feb 15;101(4):1543-50. doi: 10.1182/blood-2002-05-1585. Epub 2002 Oct 24.

Abstract

In light of the emerging concept of a protective function of the mitogen-activated protein kinase (MAPK) pathway under stress conditions, we investigated the influence of the anthracycline daunorubicin (DNR) on MAPK signaling and its possible contribution to DNR-induced cytotoxicity. We show that DNR increased phosphorylation of extracellular-regulated kinases (ERKs) and stimulated activities of both Raf-1 and extracellular-regulated kinase 1 (ERK1) within 10 to 30 minutes in U937 cells. ERK1 stimulation was completely blocked by either the mitogen-induced extracellular kinase (MEK) inhibitor PD98059 or the Raf-1 inhibitor 8-bromo-cAMP (cyclic adenosine monophosphate). However, only partial inhibition of Raf-1 and ERK1 stimulation was observed with the antioxidant N-acetylcysteine (N-Ac). Moreover, the xanthogenate compound D609 that inhibits DNR-induced phosphatidylcholine (PC) hydrolysis and subsequent diacylglycerol (DAG) production, as well as wortmannin that blocks phosphoinositide-3 kinase (PI3K) stimulation, only partially inhibited Raf-1 and ERK1 stimulation. We also observed that DNR stimulated protein kinase C zeta (PKCzeta), an atypical PKC isoform, and that both D609 and wortmannin significantly inhibited DNR-triggered PKCzeta activation. Finally, we found that the expression of PKCzeta kinase-defective mutant resulted in the abrogation of DNR-induced ERK phosphorylation. Altogether, these results demonstrate that DNR activates the classical Raf-1/MEK/ERK pathway and that Raf-1 activation is mediated through complex signaling pathways that involve at least 2 contributors: PC-derived DAG and PI3K products that converge toward PKCzeta. Moreover, we show that both Raf-1 and MEK inhibitors, as well as PKCzeta inhibition, sensitized cells to DNR-induced cytotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Bromo Cyclic Adenosine Monophosphate / pharmacology
  • Acetylcysteine / pharmacology
  • Androstadienes / pharmacology
  • Antibiotics, Antineoplastic / pharmacology
  • Antioxidants / pharmacology
  • Bridged-Ring Compounds / pharmacology
  • Cell Death / drug effects
  • Daunorubicin / pharmacology*
  • Diglycerides / biosynthesis
  • Enzyme Activation / drug effects
  • Flavonoids / pharmacology
  • Humans
  • Leukemia
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / metabolism*
  • Norbornanes
  • Phosphatidylcholines / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphorylation
  • Protein Kinase C / genetics
  • Protein Kinase C / metabolism*
  • Proto-Oncogene Proteins c-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins c-raf / metabolism*
  • Reactive Oxygen Species / pharmacology
  • Thiocarbamates
  • Thiones / pharmacology
  • Transfection
  • Tumor Cells, Cultured
  • Wortmannin

Substances

  • Androstadienes
  • Antibiotics, Antineoplastic
  • Antioxidants
  • Bridged-Ring Compounds
  • Diglycerides
  • Flavonoids
  • Norbornanes
  • Phosphatidylcholines
  • Reactive Oxygen Species
  • Thiocarbamates
  • Thiones
  • 8-Bromo Cyclic Adenosine Monophosphate
  • tricyclodecane-9-yl-xanthogenate
  • Proto-Oncogene Proteins c-raf
  • protein kinase C zeta
  • Protein Kinase C
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Acetylcysteine
  • Wortmannin
  • Daunorubicin